Scott Biller

Scott Biller is an Executive Venture Partner at GV and an independent board member for several biotechnology companies. Prior to his current advisory roles, he served as the Chief Scientific Officer at Agios Pharmaceuticals from 2010 until his retirement in 2019. During his tenure at Agios, he successfully advanced seven molecules into clinical trials, which ultimately resulted in three approved commercial medications. His more than 30-year career in pharmaceutical research and development also includes senior leadership positions at Novartis and Bristol Myers Squibb. Across his entire career, he has contributed to the discovery and development of eight approved drugs, including TIBSOVO and IDHIFA, and he currently holds directorial positions at OMass Therapeutics and Rome Therapeutics. In his current capacity, Biller focuses his expertise on guiding early-stage biotechnology ventures specializing in oncology, metabolic diseases, and novel therapeutic platforms.